Publicerad söndag 29 nov 2020, 14:45
OBS! Engelsk text.
Chronic Hepatitis B Virus - Epidemiology Forecast to 2030.
Hepatitis B is the most common serious liver infection in the world. It is caused by the hepatitis B virus that attacks and injures the liver. Millions of people are living with a chronic hepatitis B infection all around the world. The hepatitis B virus (HBV) is transmitted through blood and infected bodily fluids. It can be passed to others through direct contact with blood, unprotected sex, use of illegal drugs, unsterilized or contaminated needles.
HBV is most commonly spread through sexual contact, accounting for nearly two-thirds of acute HBV cases. It is considered as a “silent epidemic” because most people do not have symptoms when they are newly infected or chronically infected. Thus, they can unknowingly spread the virus to others and continue the silent spread of hepatitis B. Most hepatitis B infections clear up within 1-2 months without treatment. When the infection lasts more than 6 months, it can develop into chronic hepatitis B, which can lead to chronic inflammation of the liver, cirrhosis (scarring of the liver), liver cancer, and/or liver failure. HBV infection has been identified as an important cause of chronic hepatitis (35.9%) and liver cirrhosis (44.2%).
For more information please click on:
Chronic Hepatitis B Virus - Epidemiology Forecast to 2030
The symptoms of hepatitis B include fatigue, poor appetite, stomach pain, fever, nausea, vomiting, and occasionally joint pain, hives, or rash. Urine may become darker in colour, and then jaundice (yellowing of the skin and whites of the eyes) may appear. Adults are more likely than children to develop symptoms; however, up to 50% of adults who have the acute infection do not have any symptoms. The symptoms may appear within 6 weeks to 6 months after exposure, but usually 4 months. The virus can be found in blood and other body fluids several weeks before symptoms appear and generally persists for several months afterwards.
This condition is diagnosed with blood tests, which are also used to monitor its effects on the liver. For chronic cases, a liver biopsy may be needed. A biopsy is the removal of a sample of liver tissue for testing.
Key Questions Answered:
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CHB?
- What are the key findings pertaining to the CHB epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
- What would be the total number of patients of CHB across the 7MM during the study period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
- At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
- What are the various recent and upcoming events which are expected to improve the diagnosis of CHB?
In light of the current Covid-19 Pandemic, it may be possible to have this report customised.
To order online, please click here. If you require any assistance, feel free to contact me.
Thank you for your consideration.
Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.